Abstract
It was previously shown that the estrogen-receptor negative breast cancer cell line MBA-MD-231 expresses high levels of A2B adenosine receptors as the sole adenosine receptor subtype. These receptors couple to both, stimulation of adenylyl cyclase and a Ca2+ signal. In order to establish a potential role of A2B adenosine receptors in tumor growth and development MAPK signaling was investigated in these breast cancer cells. Although it is known that A2B adenosine receptors may stimulate MAPK it was found that in MBA-MD-231 cells ERK1/2 phosphorylation is reduced upon agonist-stimulation of A2B adenosine receptors. This reduction is also triggered by forskolin, but abolished by the PKA inhibitor H89, suggesting an important role for the cAMP-PKA pathway. Likewise, a role for intracellular Ca2+ was established as the Ca2+ chelator 1,2-bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid, tetraacetoxymethyl ester (BAPTA-AM) abolished the reduction of ERK1/2 phosphorylation triggered by A2B stimulation. It was shown that various pathways downstream from A2B adenosine receptors resulted in a stimulation of MAPK phosphatase-1 (MKP-1) which dephosphorylates phospho ERK1/2, and thus plays a critical role in the regulation of the phosp...Continue Reading
References
Nov 12, 1993·Science·S J Cook, F McCormick
Aug 1, 1996·Kidney International·M HanedaR Kikkawa
Aug 7, 1997·Oncogene·J C ScimecaS Meloche
Feb 12, 1998·Naunyn-Schmiedeberg's Archives of Pharmacology·K N KlotzM J Lohse
May 9, 2000·Biochemical and Biophysical Research Communications·K N PandeyJ W Boyle
Jan 9, 2001·Journal of Cellular Physiology·G OhanaP Fishman
Apr 25, 2002·Molecular and Cellular Biology·Amardeep S DhillonWalter Kolch
Oct 31, 2002·The Journal of Investigative Dermatology·Stefania MerighiPier Andrea Borea
Jul 2, 2003·Cellular Signalling·Gunnar Schulte, Bertil B Fredholm
Jul 17, 2003·The Journal of Biological Chemistry·Lea MadiPnina Fishman
Oct 11, 2003·Pharmacology & Therapeutics·Stefania MerighiPier Andrea Borea
Feb 14, 2004·Circulation Research·Rung-chi LiLynda A Sellers
Jul 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lea MadiPnina Fishman
Mar 9, 2005·British Journal of Pharmacology·Mojtaba PanjehpourKarl-Norbert Klotz
Oct 17, 2008·Pharmacological Reviews·Tarek BoutrosPeter Metrakos
Dec 10, 2008·Expert Opinion on Therapeutic Targets·Silvio NaviglioGennaro Illiano
Jul 30, 2009·Handbook of Experimental Pharmacology·P FishmanP A Borea
Aug 8, 2009·Cancer Biology & Therapy·Silvio NaviglioGennaro Illiano
Feb 16, 2010·Experimental Cell Research·Bertil B Fredholm
Oct 5, 2010·Biochimica Et Biophysica Acta·Stefania GessiPier Andrea Borea
Feb 10, 2011·Pharmacological Reviews·Bertil B FredholmChrista E Müller
May 12, 2011·Endocrinology·Laura BrionCristina Paz
May 19, 2011·Advances in Pharmacology·Stefania GessiPier Andrea Borea
Apr 17, 2013·Proceedings of the National Academy of Sciences of the United States of America·Catharina RuppertKristina Lorenz
Nov 15, 2013·Nature Reviews. Cancer·Luca AntonioliGyörgy Haskó
Apr 27, 2017·The Journal of Biological Chemistry·Monica Galaz-MontoyaTheodore G Wensel
Citations
Feb 11, 2020·International Reviews of Immunology·Marharyta Zyma, Rafał Pawliczak
Oct 20, 2019·International Journal of Molecular Sciences·Zhan-Guo Gao, Kenneth A Jacobson
Apr 16, 2019·Frontiers in Cellular Neuroscience·Kenneth A JacobsonZhan-Guo Gao
Jul 25, 2019·Naunyn-Schmiedeberg's Archives of Pharmacology·Marthe Koussémou, Karl-Norbert Klotz
May 14, 2021·Purinergic Signalling·M Reyna-JeldesF G Vázquez-Cuevas
Sep 10, 2021·Journal of Nanobiotechnology·Xiao ZhaiMing Li